News

BARDA is a part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services. The product, which represents $139.7m of the

Zurnai is indicated for treating suspected or known opioid overdose in adults and pediatric patients aged 12 years and older. It is not a substitute for emergency medical

One indication is for treating adults with priorly treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pancreatic neuroendocrine tumours (pNET). Other one is for use in adults

The territories include Japan, South Korea, and several Southeast Asian countries, including Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia. CBT-001 is an investigational emulsified nintedanib ophthalmic formulation

The decision comes as BioNTech has chosen not to participate further in the programme under the existing collaboration agreement. Despite this change, Genmab will still be required to

Classified as human IL-12 and -23 antagonists, Steqeyma and Steqeyma are I.V. biosimilar products to reference medicine Stelara. The treatment is authorised for use in adults with moderately

The funding initiative was spearheaded by Fairmount and Venrock Healthcare Capital Partners, with contributions from Driehaus Capital Management, Deep Track Capital, Franklin Templeton, Braidwell and RTW Investments. The

The company will leverage its AbReptor protein degradation platform for advancing the programmes across various oncology indications with potential applications in other areas. STIC Investments and DSC Investment

Formerly known as ALPHA-1062, the therapy is said to have a dual mechanism of action aimed at improving tolerability and maintaining the efficacy of galantamine, its active moiety.